Key result
Xinkeshu tablets significantly reduced anxiety and depression scores (HADS-a/HADS-d and PHQ-9) compared to placebo in CAD patients following percutaneous revascularization (P < 0.05).
Why the study?
Depression and anxiety symptoms affect a large proportion of patients with CAD and are linked to increased mortality, but the therapeutic efficacy of Xinkeshu tablets and their relation to plasma cytokines remained unclear.
Do Xinkeshu tablets improve depression and anxiety symptoms in patients with coronary artery disease following percutaneous revascularization?
Comparison
Xinkeshu tablets vs placebo
Design
Double-blind, randomized, placebo-controlled trial
Follow-up
12 weeks
Authors
Loading...
Xinkeshu reduced anxiety and depressive symptoms in CAD patients; supports adjunctive use and extends cytokine association data for larger trials.
RCT (n=60)
Double-blind
randomized
Do Xinkeshu tablets improve depression and anxiety symptoms in patients with coronary artery disease following percutaneous revascularization?
p-value: p=< 0.05
Xinkeshu tablets significantly reduced anxiety and depression scores in CAD patients post-revascularization, potentially mediated by changes in inflammatory cytokines.
Ma et al. (2019) conducted an RCT in Coronary artery disease with depression or anxiety symptoms (n=60). Xinkeshu tablets vs. Placebo was evaluated on Depressive/anxiety symptoms (HADS-a/HADS-d and PHQ-9 scores) (p=< 0.05). Xinkeshu tablets significantly reduced anxiety and depression scores (HADS-a/HADS-d and PHQ-9) compared to placebo in CAD patients following percutaneous revascularization (P < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: